CellWell record HH-459512
Increased HbA1c relative to actual glycemic control in patients treated with sodium-glucose cotransporter 2 inhibitors
Keigo Mizutani; Eita Uenishi; Takeshi Onoue; Ryutaro Maeda; Koji Suzuki; Tomoko Handa; Tomoko Kobayashi; Shintaro Iwama; Takashi Miyata; Mariko Sugiyama; Daisuke Hagiwara; Hidetaka Suga; Masaki Okazaki; Atsushi Hashizume; Hiroshi Arima
2026
In plain language
In 136 patients with diabetes at two Japanese centers, those taking SGLT2 inhibitors had a larger gap between HbA1c and glucose-monitoring estimates than those on other oral drugs.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-459512
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.